Cystitis treatment with high dose chondroitin sulfate
View Patent ↗Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.
1. A pharmaceutical composition adapted for instillation to the bladder of a patient, the composition comprising a unit dose of chondroitin sulfate in an amount of at least 350 mgs and an aqueous vehicle in a volume of from 20 mL to 100 mL, wherein the maximum amount of chondroitin sulfate in the composition is equal to the solubility maximum for chondroitin sulfate in said vehicle.
2. The pharmaceutical composition of claim 1 , wherein the unit dose of chondroitin sulfate is in an amount of from 350 mgs to 1200 mgs.
3. The pharmaceutical composition of claim 1 , wherein the unit dose of chondroitin sulfate is in an amount of from 350 mgs to 600 mgs.
4. A pharmaceutical composition comprising 400 mgs of chondroitin sulfate in 20 mL of an aqueous vehicle.
5. A pharmaceutical composition, in the form of a sterile chondroitin sulfate solution, consisting of 400 mgs of chondroitin sulfate and 20 mL of an aqueous vehicle.
6. The pharmaceutical composition of claim 1 , wherein the aqueous vehicle is phosphate-buffered saline.
7. The pharmaceutical composition of claim 1 , wherein the composition is contained within a vial.
8. The pharmaceutical composition of claim 1 , wherein the composition is pH 7.2, sterile, and contained within a vial.
9. A method of treating cystitis in a subject in need thereof, the method comprising administering to the subject by installation to the bladder the pharmaceutical composition of claim 1 .
10. A method of treating cystitis in a subject in need thereof, the method comprising treating the subject with a pharmaceutical composition comprising chondroitin sulfate in an amount of 400 mg and an aqueous vehicle in a volume of 20 mL.
11. The method according to claim 9 , wherein the aqueous vehicle is phosphate-buffered saline.
12. The method according to claim 9 , wherein the cystitis is interstitial cystitis.
13. The method according to claim 12 , wherein instilling the pharmaceutical composition into the bladder or urinary tract of the subject comprises instilling at least once weekly for a period of at least 6 weeks.
14. The method according to claim 12 , wherein instilling the pharmaceutical composition into the bladder or urinary tract of the subject comprises instilling at least twice weekly for a period of at least 6 weeks.
15. The pharmaceutical composition of claim 2 , wherein the vehicle is in a volume of from 20 mL to 50 mL.
16. The pharmaceutical composition of claim 1 , wherein the composition is a 2% (w/v) composition.